Peptide Library
Every compound profile on Peptide Insider, filterable by research area, evidence level and regulatory status. Each entry states what the published research shows — and where it stops.
10 compounds
Also known as Body Protection Compound 157, PL 14736, PL-10
Tissue & Recovery Research • Gastrointestinal Research
A synthetic 15-amino-acid sequence derived from a protein found in human gastric juice. Extensively studied in rodent injury models; almost no published controlled human data.
View research profile →
Also known as CJC-1295 with DAC, DAC:GRF, Drug Affinity Complex GHRH analog
Growth Hormone & Endocrine Research
A long-acting analog of growth hormone-releasing hormone. Early human trials established that it raises GH and IGF-1 for days after a single dose — but hormone levels are a surrogate, not a clinical outcome.
View research profile →
Also known as Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper(II), GHK
Skin & Dermatology Research • Tissue & Recovery Research • Longevity Research
A naturally occurring three-amino-acid peptide that binds copper, found in human plasma and widely used as a topical cosmetic ingredient. Strong mechanistic and gene-expression data; thin controlled clinical evidence.
View research profile →
Also known as NNC 26-0161, Ipamorelin acetate
Growth Hormone & Endocrine Research • Gastrointestinal Research
A selective growth hormone secretagogue that reached Phase 2 human trials for postoperative ileus — where it missed its primary endpoint. One of the few compounds in this space with a published, well-conducted negative trial.
View research profile →
Also known as Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide
Mitochondrial Research • Metabolic Research • Longevity Research
A 16-amino-acid peptide encoded by mitochondrial DNA rather than the nuclear genome. Striking metabolic effects in mice; no published controlled human trials.
View research profile →
Also known as LY3437943, Triple hormone receptor agonist, GGG tri-agonist
Metabolic Research
An investigational triple agonist at the GIP, GLP-1 and glucagon receptors. Phase 3 results report the largest mean weight reductions yet published for a pharmacological agent — and it is not approved.
View research profile →
Also known as Ozempic, Wegovy, Rybelsus
Metabolic Research
A long-acting GLP-1 receptor agonist and one of the most extensively trialled peptide drugs ever developed, with approvals spanning diabetes, weight management, cardiovascular risk reduction and liver disease.
View research profile →
Also known as Thymosin β4, Tβ4, TMSB4X (gene)
Tissue & Recovery Research • Immune Research
Thymosin β4 is a naturally occurring 43-amino-acid actin-binding peptide that has completed randomised human trials as an eye drop. "TB-500" is a shorter synthetic fragment sold as a research chemical — and the two are not interchangeable.
View research profile →
Also known as Egrifta, Egrifta SV, Egrifta WR
Growth Hormone & Endocrine Research • Metabolic Research
The only GHRH-class analog with FDA approval. Approved narrowly — for reducing excess visceral abdominal fat in adults with HIV and lipodystrophy — and explicitly not indicated for weight loss.
View research profile →
Also known as Mounjaro, Zepbound, LY3298176
Metabolic Research
A dual GIP and GLP-1 receptor agonist. The first drug approved for obstructive sleep apnoea in adults with obesity, and the compound that established that multi-receptor agonism outperforms GLP-1 alone.
View research profile →
Each compound carries one of five labels describing its published research record. The full criteria — and what each label explicitly does not mean — are set out in the evidence ratings methodology.
Multiple adequately powered randomised controlled trials in humans, with published results.
Human trials exist but are small, early phase, single-site, or limited to surrogate endpoints.
Evidence is confined to animal models, tissue, or cell-culture work. No meaningful human data.
Only a small number of studies exist, or the available studies have serious methodological limits.
There is not enough published, independently verifiable research to characterise the compound.